Additionally, previous work in our lab has also demonstrated that the modulation of glycolysis can increase the sensitivity to chemotherapeutics; for example, Xu et al. [23] demonstrated that ABT737 reversed the resistance to cisplatin by targeting the glucose metabolism in human ovarian cancer cells, and Xiang et al. [24] demonstrated that S1 exerts anti-cancer effects in SKOV3 cells by interrupting the glucose metabolism and inducing apoptosis involving the activation of SIRT3, while the combination of the glycolysis inhibitor 2-DG and S1 is able to further enhance the cytotoxicity. Here, SIRT3 is linked to ovarian cancer.